Loading news...
Surrozen, Inc. (NASDAQ: SRZN - Get Free Report) major shareholder Group Gp Lp Column III bought 18,052 shares of Surrozen stock in a transaction dated Tuesday, January 20th. The shares were acquired at an average cost of $19.60 per share, with a total value of $353,819.20. Following the completion of the purchase, the insider owned 1,016,658
Surrozen, Inc. (NASDAQ: SRZN - Get Free Report) major shareholder Group Gp Lp Column III purchased 11,893 shares of the company's stock in a transaction that occurred on Thursday, January 15th. The stock was acquired at an average cost of $19.89 per share, with a total value of $236,551.77. Following the purchase, the insider directly owned
Surrozen, Inc. (NASDAQ: SRZN - Get Free Report) Director Tim Kutzkey purchased 18,052 shares of the firm's stock in a transaction on Tuesday, January 20th. The shares were purchased at an average price of $19.60 per share, with a total value of $353,819.20. Following the completion of the acquisition, the director directly owned 1,016,658 shares of
Surrozen, Inc. (NASDAQ: SRZN - Get Free Report) Director Tim Kutzkey purchased 11,893 shares of Surrozen stock in a transaction dated Thursday, January 15th. The stock was bought at an average price of $19.89 per share, with a total value of $236,551.77. Following the acquisition, the director directly owned 1,005,732 shares of the company's stock, valued
Surrozen, Inc. (NASDAQ: SRZN - Get Free Report) Director Tim Kutzkey acquired 5,523 shares of the business's stock in a transaction that occurred on Wednesday, January 14th. The shares were acquired at an average cost of $19.99 per share, with a total value of $110,404.77. Following the transaction, the director directly owned 999,429 shares in the
Surrozen, Inc. (NASDAQ: SRZN - Get Free Report) major shareholder Group Gp Lp Column III acquired 5,523 shares of the stock in a transaction dated Wednesday, January 14th. The shares were bought at an average cost of $19.99 per share, with a total value of $110,404.77. Following the transaction, the insider directly owned 999,429 shares of
Surrozen, Inc. (NASDAQ: SRZN - Get Free Report) major shareholder Group Gp Lp Column III bought 12,470 shares of the company's stock in a transaction on Tuesday, January 13th. The shares were bought at an average cost of $19.80 per share, for a total transaction of $246,906.00. Following the transaction, the insider directly owned 996,502 shares
Surrozen, Inc. (NASDAQ: SRZN - Get Free Report) Director Tim Kutzkey purchased 12,470 shares of the business's stock in a transaction that occurred on Tuesday, January 13th. The stock was bought at an average price of $19.80 per share, for a total transaction of $246,906.00. Following the acquisition, the director owned 996,502 shares of the company's
Surrozen, Inc. (NASDAQ: SRZN - Get Free Report) Director Tim Kutzkey bought 15,100 shares of the business's stock in a transaction on Tuesday, January 6th. The stock was bought at an average cost of $19.89 per share, with a total value of $300,339.00. Following the transaction, the director owned 989,893 shares in the company, valued at
Surrozen, Inc. (NASDAQ: SRZN - Get Free Report) major shareholder Group Gp Lp Column III purchased 15,100 shares of the firm's stock in a transaction dated Tuesday, January 6th. The stock was purchased at an average cost of $19.89 per share, for a total transaction of $300,339.00. Following the acquisition, the insider owned 989,893 shares of
SOUTH SAN FRANCISCO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway, with a focus on severe eye diseases, today announced that Company management will present at two upcoming healthcare investor conferences.
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway, with a focus on severe eye diseases, today announced that on November 6, 2025, Surrozen granted inducement stock option awards covering an aggregate of 50,000 shares of Surrozen common stock to the newly appointed Chief Financial Officer, Andrew P.
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repair and regeneration, with a focus on severe eye diseases, today announced financial results for the third quarter ended September 30, 2025, and provided a business update.
SOUTH SAN FRANCISCO, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway, with a focus on severe eye diseases, today announced that on September 2, 2025, Surrozen granted inducement stock option awards covering an aggregate of 45,710 shares of Surrozen common stock to four recently hired non-executive employees as an inducement material to their acceptance of employment with Surrozen.
Surrozen Reports Q2 Profit on Gains
Daniel Chao, M.D., Ph.D., joins Surrozen as Vice President of Clinical Development Surrozen forms Clinical Advisory Board comprised of leading retinal specialists Data Presentations at Association for Research in Vision and Ophthalmology Annual Meeting and Clinical Trials at the Summit SOUTH SAN FRANCISCO, Calif.
SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repair and regeneration, with a focus on severe eye diseases, today announced that Company management will present at an upcoming healthcare investor ophthalmology focused conference.
Surrozen (SRZN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.